Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL
inhalation solution delivered by the Respimat® inhaler for four weeks in patients with
chronic obstructive pulmonary disease (COPD). The selection of the optimum dose(s) will be
based on bronchodilator efficacy (how well it helps your breathing), safety evaluations and
pharmacokinetic evaluations (the amount of the medication found in your blood).